Increased risk of 20%? Dr. JimThorp, obstetrician/gynecologist who led the fight against the COVID mRNA technology gene injections as to harms on the fetus, mother, newborn, as has Dr. Naomi Wolf, are

likely going crazy, livid, angered by a substack by our brilliant colleague Karen Kingston who highlights study of 4,610 Women Hospitalized post-mRNA Vaccination Due to increased Severe Bleeding!!

A risk increased by 20% following the primary vaccination; This association was observed for primary vaccination doses (OR 1.20 [1.07; 1.35]), i.e. an increase in risk of 20%

‘New Study of 4,610 Women Hospitalized post-mRNA Vaccination Due to Severe Bleeding

A new study shows increased risk of severe bleeding post-mRNA vaccination. In 2021, Pfizer launched Myfembree - a $16,000 per year treatment for women who suffer from heavy menstrual bleeding.’

New Study of 4,610 Women Hospitalized post-mRNA Vaccination Due to Severe Bleeding

‘February 9, 2024: Per MedScape, the French clinical-analysis group EPI-PHARE recently completed an independent study of the French National Agency for the Safety of Medicines (ANSM) and the French National Health Insurance (CNAM) to determine if there’s a correlation between heavy-to-severe menstrual bleeding and mRNA vaccination.

Per MedScape, of the 4,610 women aged 15-50 years of age who were hospitalized due to heavy menstrual bleeding between May 12, 2021 and August 31, 2022; 99.8% of the women had received Comirnaty (Pfizer) or Spikevax (Moderna) as their last COVID-19 mRNA vaccine prior to hospitalization. Hospitalization occurred within 1-3 months post COVID-19 mRNA injection. The authors concluded;

"This study provides new evidence supporting the existence of an increased risk for heavy menstrual bleeding following COVID-19 vaccination with mRNA vaccines."''

‘France — Cases of menstrual disorders, particularly abnormally heavy menstrual bleeding, have been reported following RNA vaccination against COVID-19.

This safety signal was confirmed and added to the summaries of product characteristics (SmPCs) and package inserts for mRNA vaccines in October 2022.

However, to date, few studies have made it possible to properly measure this risk.

To do this, the scientific interest group in the epidemiology of French health products ANSM-Cnam EPI-PHARE therefore carried out a study whose objective was to evaluate the risk of heavy menstrual bleeding having been the subject of a hospital care after vaccination with Covid-19 vaccines in France.

“This study provides new arguments in favor of the existence of an increased risk of heavy menstrual bleeding following vaccination against COVID-19 with an mRNA vaccine,” indicate the authors.

Study details

The study focused on all women aged 15-50 who were diagnosed with heavy menstrual bleeding in hospital between May 12, 2021 and August 31, 2022 (identified in the National Health Data System - SNDS), or 4,610 women.

Each was randomly matched to up to 30 women who had not been hospitalized for a problem of abnormal genital bleeding and who had the same characteristics in terms of age, department of residence, social deprivation index of the municipality of residence, and contraceptive method.

Excluded were women who had become pregnant in the previous 18 months or had a hysterectomy or a bleeding disorder in the previous five years.

At the time of the study, 71% of cases and 70% of controls had received at least one dose of Covid-19 vaccine, and among these vaccinated people, the last dose received was a primary vaccination dose (first or second dose ) for 68% and 66%. The last vaccine received was an mRNA vaccine (Comirnaty or Spikevax) for 99.8%.

A risk increased by 20% following the primary vaccination

The analysis shows that, compared to control women, women treated in hospital for heavy menstrual bleeding had more often received their last dose of mRNA vaccine (Comirnaty or Spikevax) within 1 to 3 months. previous ones. This association was observed for primary vaccination doses (OR 1.20 [1.07; 1.35]), i.e. an increase in risk of 20%, but not found for booster doses (OR 1.07 [0, 92; 1.26]).

It particularly concerned women residing in socially disadvantaged municipalities (OR 1.28 [1.07; 1.52]) and women not using hormonal contraception (OR 1.28 [1.11; 1.48] ]).

The risk did not appear increased beyond 3 months after the primary vaccination. The researchers specify that the increased risk could have occurred earlier given the probable delay between the first symptoms and treatment in hospital.

Assuming a causal relationship, the estimated number of cases attributable to primary vaccination was 8 cases per million vaccinated women, i.e. a total number of 103 cases among all women aged 15-50 who were vaccinated. vaccinated in France between May 12, 2021 and August 31, 2022.’